Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-214374
Abstract: To date, all available data regarding the switch from bio-originator to its biosimilar are reassuring, and the switch has been recommended as a shared patient–physician decision in recent consensus-based recommendations.1 In particular, the Norway's infliximab… read more here.
Keywords: originator; long term; term follow; originator infliximab ... See more keywords